Ficlatuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Ficlatuzumab
DrugBank Accession Number
DB11680
Background

Ficlatuzumab has been used in trials studying the treatment of Acute Myeloid Leukemia, Non-small Cell Lung Cancer, Mullerian Mixed Tumor of Ovary, Relapsed Acute Myeloid Leukemia, and Refractory Acute Myeloid Leukemia, among others.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Ficlatuzumab

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Ficlatuzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Ficlatuzumab.
AducanumabThe risk or severity of adverse effects can be increased when Ficlatuzumab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ficlatuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Ficlatuzumab.
AmivantamabThe risk or severity of adverse effects can be increased when Ficlatuzumab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Ficlatuzumab is combined with Anifrolumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Ficlatuzumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Ficlatuzumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Ficlatuzumab.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
77E89833TG
CAS number
1174900-84-5

References

General References
Not Available
PubChem Substance
347911226
Wikipedia
Ficlatuzumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentHead and Neck Basaloid Carcinoma / Head and Neck Carcinoma / HNSCC / Oropharyngeal Cancers / Recurrent Head and Neck Squamous Cell Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Squamous Cell Carcinoma of Unknown Primary Origin / Stage IV Lip and Oral Cavity Squamous Cell Carcinoma / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Stage IV Oropharyngeal Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma1
2TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2WithdrawnTreatmentAcute Myeloid Leukemia (AML)1
1CompletedOtherSquamous Cell Carcinoma Head and Neck Cancer (HNSCC) / Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)1
1CompletedTreatmentHepatic Metastases / Solid Malignant Tumors1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1TerminatedOtherSquamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)1
1TerminatedTreatmentAcute Myeloid Leukemia (AML) / Refractory Acute Myelogenous Leukemia (AML) / Relapsed Acute Myelogenous Leukemia (AML)1
1, 2CompletedTreatmentLung Cancers / Neoplasms, Lung / Non-Small Cell Lung Carcinoma (NSCLC) / Respiratory Tract Neoplasms1
Not AvailableNo Longer AvailableNot AvailableMullerian Mixed Tumor of Ovary1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 20, 2016 20:39 / Updated on February 21, 2021 18:53